Minocycline in active rheumatoid arthritis
The DOI matches its Crossref record.
Abstract
Objective. To determine the efficacy of minocycline in the treatment of rheumatoid arthritis (RA). Methods. Minocycline (maximal oral daily dose 200 mg) or placebo was administered in a 26‐week, randomized, double‐blind study to 80 patients with active RA, who were treated or had previously been treated with at least one disease‐modifying antirheumatic drug. Results. There were 15 premature discontinuations: 6 (5 taking minocycline) because of adverse effects, 8 (all taking placebo) because of lack of efficacy, and 1 (taking placebo) because of intercurrent illness. There was a statistically significant improvement in the minocycline group over the placebo group. There was a pronounced improvement in laboratory parameters of disease activity; however, improvement in clinical parameters was less impressive. The observed adverse effects attributable to minocycline were mainly gastrointestinal symptoms and dizziness. Conclusion. The results of the present study suggest that minocycline is beneficial and relatively safe in RA patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guidelines for the management of rheumatoid arthritis: 2002 Update
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) · Arthritis & Rheumatism · doi:10.1002/art.10148 · Cited by 1,185
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
McCarey, D. W., McInnes, I. B., Madhok, R., Hampson, R., Scherbakova, O., Ford, I., Capell, H. A., & Sattar, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16449-0 · Cited by 818
Tetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Angiogenesis: Implications for rheumatoid arthritis
Koch, A. E. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199806)41:6<951::aid-art2>3.0.co;2-d · Cited by 504
The Gut Microbiota in Immune-Mediated Inflammatory Diseases
Forbes, J. D., Van Domselaar, G., & Bernstein, C. N. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01081 · Cited by 429
Scope, A., Agero, A. L. C., Dusza, S. W., Myskowski, P. L., Lieb, J. A., Saltz, L., Kemeny, N. E., & Halpern, A. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6987 · Cited by 278
Metalloproteases and inhibitors in arthritic diseases
Martel-Pelletier, J., Welsch, D. J., & Pelletier, J.-P. (2001) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2001.0195 · Cited by 270
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Central Proinflammatory Cytokines and Pain Enhancement
Wieseler-Frank, J., Maier, S. F., & Watkins, L. R. (2005) · Neurosignals · doi:10.1159/000087655 · Cited by 198
Mangat, P., Wegner, N., Venables, P. J., & Potempa, J. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3000 · Cited by 111
Metadata
- Authors
- Kloppenburg, M., Breedveld, F. C., Terwiel, J. P. H., Mallee, C., & Dijkmans, B. A. C.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1994-05
- Volume
- 37
- Issue
- 5
- Pages
- 629-636
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2140668133
- Cited by
- 172
- References
- 0
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.